Adicet Bio, Inc. Common Stock
ACETAdicet Bio, Inc. is a biotechnology company focused on the development of allogeneic cell therapies for cancer and other diseases. Leveraging innovative immune cell engineering technologies, Adicet aims to create off-the-shelf, highly effective treatments that harness the body's immune system to target and destroy disease cells.
Company News
Johnson & Johnson announced positive Phase 2b results for nipocalimab, an experimental FcRn blocker for treating systemic lupus erythematosus (SLE). The JASMINE study of 228 subjects met its primary endpoint and key secondary endpoints, with a favorable safety profile. The company plans to initiate Phase 3 trials. The lupus treatment market inclu...
ACET ($ACT), a blockchain-powered DeFi platform, has partnered with the Royal Office of H.H. Sheikh Ahmed Bin Faisal Al-Qassimi to drive blockchain adoption and financial innovation in the UAE, including integrating ACET ($ACT) into a $3.9 billion casino resort project.
Acme Worawat, founder of the ACET (ACT) digital currency, has proposed integrating Bitcoin into Thailand's economic framework, including utilizing it as part of the country's reserve fund. The initiative aims to position Thailand as a global leader in Blockchain technology and attract global crypto investments.
Adicet Bio (ACET) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
